Article

Inflammation

, Volume 31, Issue 4, pp 215-221

Hepatoprotective Effect of Infliximab, an Anti-TNF-α Agent, on Carbon Tetrachloride-Induced Hepatic Fibrosis

  • Ibrahim Halil BahceciogluAffiliated withDepartment of Gastroenterology, Faculty of Medicine, Fırat University
  • , Suleyman Serdar KocaAffiliated withDepartment of Internal Medicine and Rheumatology, Faculty of Medicine, Fırat UniversityTıp Fakultesi, Romatoloji, Fırat universitesi Email author 
  • , Orhan Kursat PoyrazogluAffiliated withDepartment of Gastroenterology, Faculty of Medicine, Fırat University
  • , Mehmet YalnizAffiliated withDepartment of Gastroenterology, Faculty of Medicine, Fırat University
  • , Ibrahim Hanifi OzercanAffiliated withDepartment of Pathology, Faculty of Medicine, Fırat University
  • , Bilal UstundagAffiliated withDepartment of Biochemistry, Faculty of Medicine, Fırat University
  • , Kazim SahinAffiliated withDepartment of Animal Nutrition, Faculty of Veterinary, Fırat University
  • , Adile Ferda DagliAffiliated withDepartment of Pathology, Faculty of Medicine, Fırat University
  • , Ahmet IsikAffiliated withDepartment of Internal Medicine and Rheumatology, Faculty of Medicine, Fırat University

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

To assess the effect of infliximab, an anti-tumor necrosis factor (TNF)-α agent, on the carbon tetrachloride (CCl4)-induced hepatic fibrosis in rats. Rats were randomized into three groups (n = 9). The control group received only intraperitoneal (i.p.) olive oil. Hepatic fibrosis was induced by repeated i.p. injections of 1.5 ml/kg CCl4 (1:3 mixture with olive oil) for 5 weeks in the remaining two groups which were also injected subcutaneous saline or 2 mg/kg infliximab. Infliximab reduced the levels of aspartate aminotransferase and alanine aminotransferase (p < 0.05 for both). The scores of hepatic necrosis, inflammation and fibrosis, and expression of α-smooth muscle actin were lower in the infliximab-treated group than the CCI4-treated group (p < 0.01, p < 0.001, p < 0.01, p < 0.001, respectively). However, there was no significant difference in terms of liver tissue and plasma malondialdehyde, and serum TNF-α levels, while infliximab relatively reduced the level of transforming growth factor-β1 (373.0 ± 153.1 vs. 280.8 ± 127.1 pg/ml). Treatment with infliximab attenuated the necro-inflammation and fibrogenesis in the CCI4-induced hepatic fibrosis, and thus it might be effective as a therapeutic anti-fibrotic agent.

KEY WORDS

carbon tetrachloride hepatic fibrosis infliximab